Search research articles
Contact Us
Filters
Showing results (121-130 of 155) with videos related to
Page
of 16
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 6, 2012
A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results
Riccardo Soffietti, Martin Kocher, Ufuk M Abacioglu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 2, 2019
Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC)
Eleonor Rivin Del Campo, Oscar Matzinger, Karin Haustermans, et al.
The Lancet. Oncology
|
October 11, 2018
Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group
Frédéric E Lecouvet, Daniela E Oprea-Lager, Yan Liu, et al.
Annals of Surgery
|
February 9, 2012
Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983)
Halfdan Sorbye, Murielle Mauer, Thomas Gruenberger, et al.
Lancet (London, England)
|
March 25, 2008
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
Bernard Nordlinger, Halfdan Sorbye, Bengt Glimelius, et al.
The New England Journal of Medicine
|
June 12, 2009
Duration of androgen suppression in the treatment of prostate cancer
Michel Bolla, Theodorus M de Reijke, Geertjan Van Tienhoven, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2009
Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial
Heather A Jones, Ninja Antonini, Augustinus A M Hart, et al.
JAMA Oncology
|
October 17, 2018
Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis
Amar U Kishan, Xiaoyan Wang, Wendy Seiferheld, et al.
Lancet (London, England)
|
October 23, 2012
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)
Michel Bolla, Hein van Poppel, Bertrand Tombal, et al.
The Lancet. Oncology
|
December 16, 2014
Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial
Harry Bartelink, Philippe Maingon, Philip Poortmans, et al.
Page
of 16
Search research articles
Search
Showing results (121-130 of 155) with videos related to
Sort By:
Page
of 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 6, 2012
A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results
Riccardo Soffietti, Martin Kocher, Ufuk M Abacioglu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 2, 2019
Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC)
Eleonor Rivin Del Campo, Oscar Matzinger, Karin Haustermans, et al.
The Lancet. Oncology
|
October 11, 2018
Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group
Frédéric E Lecouvet, Daniela E Oprea-Lager, Yan Liu, et al.
Annals of Surgery
|
February 9, 2012
Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983)
Halfdan Sorbye, Murielle Mauer, Thomas Gruenberger, et al.
Lancet (London, England)
|
March 25, 2008
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
Bernard Nordlinger, Halfdan Sorbye, Bengt Glimelius, et al.
The New England Journal of Medicine
|
June 12, 2009
Duration of androgen suppression in the treatment of prostate cancer
Michel Bolla, Theodorus M de Reijke, Geertjan Van Tienhoven, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2009
Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial
Heather A Jones, Ninja Antonini, Augustinus A M Hart, et al.
JAMA Oncology
|
October 17, 2018
Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis
Amar U Kishan, Xiaoyan Wang, Wendy Seiferheld, et al.
Lancet (London, England)
|
October 23, 2012
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)
Michel Bolla, Hein van Poppel, Bertrand Tombal, et al.
The Lancet. Oncology
|
December 16, 2014
Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial
Harry Bartelink, Philippe Maingon, Philip Poortmans, et al.
Page
of 16